ENDRA Life Sciences (NDRA) Total Current Liabilities (2016 - 2026)

ENDRA Life Sciences has disclosed Total Current Liabilities across 11 years of filings, most recently posting $835440.0 for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 47.66% year-over-year to $835440.0; the TTM figure through Mar 2026 stood at $835440.0 (up 47.66% YoY), while the FY2025 annual figure was $750956.0, up 24.08% from the prior year.
• Total Current Liabilities advanced to $835440.0 in Q1 2026, from $750956.0 in the prior quarter.
• Over the last five years, Total Current Liabilities for NDRA reached as high as $2.2 million in Q3 2023 and fell as low as $565785.0 in Q1 2025.
• The 5-year median for Total Current Liabilities is $1.2 million (2024), against an average of $1.2 million.
• Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 77.32% — and 2024, when it sank 62.48%.
• A 5-year view of Total Current Liabilities shows it stood at $1.7 million in 2022, then plunged by 46.99% to $903095.0 in 2023, then plunged by 32.98% to $605230.0 in 2024, then grew by 24.08% to $750956.0 in 2025, then gained by 11.25% to $835440.0 in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $835440.0, $750956.0, and $800307.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.